Clinical translation of a patient-specific scaffold-guided bone regeneration concept in four cases with large long bone defects

Markus Laubach a,b,c, Sinduja Suresh b,c, Buddhi Herath b,c, Marie-Luise Wille b,c,d, Heide Delbrück a, Hatem Alabdulrahman c, Dietmar W. Hutmacher b,c,d,e,*, Frank Hildebrand a,**

a Department of Orthopaedics, Trauma and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany
b Australian Research Council (ARC) Training Centre for Multiscale 3D Imaging, Modelling, and Manufacturing (M3D Innovation), Queensland University of Technology, Brisbane, QLD, 4000, Australia
c Centre for Biomedical Technologies, School of Mechanical, Medical and Process Engineering, Queensland University of Technology, Brisbane, QLD, 4059, Australia
d Australian Research Council (ARC) Training Centre for Multiscale 3D Imaging, Modelling, and Manufacturing (M3D Innovation), Queensland University of Technology, Brisbane, QLD, 4000, Australia
e ARC Training Centre for Cell and Tissue Engineering Technologies, Queensland University of Technology (QUT), Brisbane, QLD, 4000, Australia

ARTICLE INFO

Keywords:
additive manufacturing
bone defect
non-union
decalcium polycaprolactone scaffold

ABSTRACT

Background: Bone defects after trauma, infection, or tumour resection present a challenge for patients and clinicians. To date, autologous bone graft (ABG) is the gold standard for bone regeneration. To address the limitations of ABG such as limited harvest volume as well as overly fast remodelling and resorption, a new treatment strategy of scaffold-guided bone regeneration (SGBR) was developed. In a well-characterized sheep model of large extra-large tibial segmental defects, three-dimensional (3D) printed composite scaffolds have shown clinically relevant biocompatibility and osteoconductive capacity in SGBR strategies. Here, we report four challenging clinical cases with large complex posttraumatic long bone defects using patient-specific SGBR as a successful treatment.

Methods: After giving informed consent computed tomography (CT) images were used to design patient-specific biodegradable medical-grade polycaprolactone-tricalcium phosphate (mPCL-TCP, 80:20 wt%) scaffolds. The CT scans were segmented using Materialise Mimics to produce a defect model and the scaffold parts were designed with Autodesk Meshmixer. Scaffold prototypes were 3D-printed to validate robust clinical handling and bone defect fit. The final scaffold design was additively manufactured under Food and Drug Administration (FDA) guidelines for patient-specific and custom-made implants by Osteopore International Pte Ltd.

Results: Four patients (age: 23–42 years) with posttraumatic lower extremity large long bone defects (case 1: 4 cm distal femur, case 2: 10 cm tibia shaft, case 3: complex malununion femur, case 4: irregularly shaped defect distal tibia) are presented. After giving informed consent, the patients were treated surgically by implanting a custom-made mPCL-TCP scaffold loaded with ABG (case 2: additional application of recombinant human bone morphogenetic protein-2) harvested with the Reamer-Irrigator-Aspirator system (RIA, Synthes®). In all cases, the scaffolds matched the actual anatomical defect well and no perioperative adverse events were observed. Cases 1, 3 and 4 showed evidence of bony ingrowth into the large honeycomb pores (pores >2 mm) and fully interconnected scaffold architecture with indicative osteous bridges at the bony ends on the last radiographic follow-up (8–9 months after implantation). Comprehensive bone regeneration and full weight bearing were achieved in case 2 at follow-up 23 months after implantation.

Conclusion: This study shows the bench to bedside translation of guided bone regeneration principles into scaffold-based bone tissue engineering. The scaffold design in SGBR should have a tissue-specific morphological signature which stimulates and directs the phases from the initial host response towards the full regeneration. Thereby, the scaffolds provide a physical niche with morphology and biomaterial properties that allow cell migration, restoration and newly formed bone to align with the natural scaffold design.

https://doi.org/10.1016/j.jot.2022.04.004

Received 12 January 2022; Received in revised form 20 April 2022; Accepted 23 April 2022

2214-031X/Crown Copyright © 2022 Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
proliferation, and formation of vascularized tissue in the first one to two months, followed by functional bone formation and the capacity for physiological bone remodelling. Great design flexibility of composite scaffolds to support the one to three-year bone regeneration was observed in four patients with complex long bone defects.

The translational potential of this article: This study reports on the clinical efficacy of SGBR in the treatment of long bone defects. Moreover, it presents a comprehensive narrative of the rationale of this technology, highlighting its potential for bone regeneration treatment regimens in patients with any type of large and complex osseous defects.

1. Introduction

Bone is a dynamic, vascularized tissue which constantly remodels to adapt to mechanical demands [1]. Bone tissue healing, as a regenerative process, is initiated in response to injury and involves multiple well-orchestrated steps. Developments in surgical techniques, implant design and perioperative management have significantly improved the treatment of complex fractures and other skeletal defects caused by trauma, disease, developmental deformity, and tumour resection. Nonetheless, treatment of (large) long bone defects is complex, and the risk of malunion, delayed union and non-union remains high, with these problems frequently resulting in persistent and challenging osseous defects, which are associated with reduced quality of life and significant health care costs [2–4]. Importantly, limb-threatening trauma involving the challenging treatment of bone defects constitutes a major event in a patient's life [5].

While smaller-sized defects (<5 cm) are often treated with autologous bone graft (ABG) alone [6,7], ABG used for reconstruction of larger long bone defects (>5 cm) is associated with an increased risk of resorption [9] and structurally and functionally compromised regenerated bone in the reconstructed segment [9]. Historically, surgical methods for the treatment of large long bone defects have included vascularized free bone transfers [10–12] or the Ilizarov intercalary bone transport method [13]. However, while all of these methods are technically demanding and are associated with high complication rates [14,15], the Ilizarov method (distraction osteogenesis) in particular is characterised by a long duration of external fixation with marked patient discomfort and requiring high patient compliance [16,17]. For the last two decades, the induced membrane technique (IMT), first described by Alain Masquelet, has frequently been used as an alternative approach in cases of large long bone defects [18–22]. IMT involves a two-stage approach with implantation of a polymethylmethacrylate (PMMA) spacer in the bone defect to induce the formation of a pseudo Masquelet-membrane followed by an attempt to reconstruct the osseous defect in a second surgery, four to eight weeks after the first operation, using an ABG. Despite considerable clinical success rates for IMT, bone healing often requires multiple additional interventions, and a failure rate of 10%–15% has been reported [23–25].

In order to account for the challenges associated with the use of ABG (e.g. limited graft volume, graft resorption), there has been interest of late in the use of naturally derived and/or synthetic bone graft substitutes. However, the application of allografts is associated with very variable osteoinductive properties, high non-union rates and potential disease transmission [26,27]. Internal repair by means of neo-vascularization and bone graft replacement with new bone seems limited to the superficial surface and the ends of the allograft [28,29]. Furthermore, fractures of the allograft itself, particularly when used for larger defects, have been reported [30]. Moreover, the high cost of allografting has further spurred the development of other strategies, including the use of synthetic bone substitutes [31]. However, synthetic bone graft substitutes, such as hydroxyapatite and/or tricalcium phosphate, can only be applied in combination with ABG at a maximum ratio of 1:1 to 1:3 due to high non-union rates [26,32–35]. Thus, the clinical applicability of allografts and synthetic bone substitutes for bone defects is often limited.

The concept of scaffold-guided bone regeneration (SGBR) is rooted in the application of an additively manufactured biodegradable highly porous implant (“scaffold”) that has two functions: acting as a carrier for growth factors such as recombinant human bone morphogenetic proteins (rhBMP) 2 or 7 and/or bone grafts, and physically guiding tissue regeneration, acting as a template for both the transplanted bone graft and the host cells to ultimately result in tissue ingrowth and physiological remodelling [36]. Particularly in response to the highly dynamic tissue processes during the first three to six months of bone regeneration, the use of scaffolds provides an appropriate physical environment, as this is typically associated with disturbed local soft tissue integrity, disruption of normal vascular function, and distortion of bone marrow architecture due to surgery. Extravasation (bleeding) at the implantation site of the scaffold is contained by the surrounding tissue and develops into hematoma, neovascularization and development of osteogenic tissue and later bone remodeling. As such, specifically slow degrading scaffolds provide a temporary architecture and a suitable environment to facilitate bone regeneration [37].

SGBR rooted in combining 3D-printed biodegradable composite scaffolds with different types of ABGs, rhBMP-2 or rhBMP-7 has been successfully applied to treat large to extra-large long bone defects in several comprehensive preclinical large animal studies [38–42]. Furthermore, recent case reports indicate the successful translation of patient-specific SGBR in patients with bone loss of traumatic or tumorous origin for individual healing attempts, including the capacity for preservation of the lower extremities [43–45]. Building on both the comprehensive preclinical data sets and the first clinical case reports, in this case series, we demonstrate in great detail the versatility of the patient-specific SGBR concept for the treatment of posttraumatic long bone defects.

2. Methods and materials

SGBR, in the context of developing a patient-specific treatment concept, is an interdisciplinary and iterative process with prototype verification of both the anatomical model of the defect and the implant design (scaffold) at every stage. In the interdisciplinary meetings between clinicians and engineers, the entire treatment concept including surgical access and the intended scaffold fixation methods is discussed and simulated (Fig. 1).

2.1. Design process and manufacturing

The first step is to CT scan the patient according to standard scanning protocols. Notably, higher resolution than that normally clinically recommended for the CT scan will improve the accuracy of both the anatomical model and the scaffold design. Subsequently, the CT image data segmentation is performed on specialised software such as the Mimics Suite (Materialise, Leuven, Belgium) to extract a 3D model of the defect. It is recommended to add any fitting of surgical fixation methods (osteosynthesis plates or intramedullary nails) to the anatomical defect model prior to designing the scaffold. The defect model is then exported as an Standard Tessellation Language (STL) (surface mesh format) file and imported into a mesh manipulation software, such as Materialise 3-matic, Geomagic (3D Systems, USA) or Autodesk Meshmixer (Autodesk Inc., USA). It is strongly recommended to use 1 to 1 anatomical models of

M. Laubach et al. Journal of Orthopaedic Translation 34 (2022) 73–84
the bone defect site with and without the planned (internal) fixation to physically simulate the fit and accuracy of the scaffold.

The scaffold is designed digitally on a mesh manipulation software: a base 3D shape is created, modified slightly to fit the bone void, and strategically placed to cover and fill the defect site. In the case of segmental defects and regularly shaped voids, it is common practice to create a 3D model of the contralateral region and to use a mirrored version of this model to design the scaffold. However, in bone defects where more complex geometry matching is required, reconstruction will involve more manual intervention. Once the base shape is placed correctly, a Boolean subtraction is performed (base shape minus the defect model). This sculpts the geometry of the defect site on the base shape. The external surface of the sculpted base shape is then manually sculpted (using a wide array of digital mesh sculpting tools) around the defect to ensure adequate coverage, close fit and appropriate surface thickness throughout the scaffold so that stability is maintained. The result is two 3D models: the defective bone and a scaffold part that fits it, analogous to two 3D puzzle pieces that fit together. Fig. 2 shows a schematic of the applied design process. Multiple scaffold parts may be required to facilitate user friendly insertion by the surgeon and take into account the surgical access, incision size and clearance from the stabilisation device, all factors which are addressed during the interdisciplinary team meetings. The individually planned defect stabilization method, such as an intramedullary nail or a plate osteosynthesis influences the overall scaffold design. In addition, the scaffold parts should also be capable of being inserted into the defect void without being obstructed by the existing bone structure.

Furthermore, if fixation of the scaffolds to the host bone is required, non-porous flanges are added to the scaffold parts to fit over locations deemed biomechanically optimal on the host bone. Flanges can be created by expanding the 3D mesh at that point and performing another simple Boolean subtraction with the host bone to ensure patient-specific fit. Screws may be used to secure scaffolds onto the host bone through these flanges. To ensure that the geometrically matched scaffolds are capable of complete insertion with proper fit and to assist in pre-operative planning, prototypes of the defect model and the scaffolds are 3D printed and tested by the interdisciplinary team. Lastly, the finalised scaffold designs are shared with the medical device manufacturer Osteopore International Pte Ltd. (MedTech Hub, Singapore) for fabrication of the patient-specific scaffolds by using medical-grade polycaprolactone-tricalcium phosphate (mPCL-TCP, 80:20 wt%). A melt extrusion 3D printing technology is used to manufacture an alternating rectilinear infill pattern of 0°, 60° and 120° creating triangular pores with a size of 2–3 mm. Briefly, in accordance with Food and Drug Administration (FDA) guidelines, the patient-specific scaffolds were manufactured in a clean-room environment adhering to International Organization for Standardization (ISO) 14644. Further, under the ISO 13485-compliant quality management system of Osteopore all implants were packed ISO 11607 compliant and sterilized with gamma irradiation according to ISO 11137 guidelines.

3. Results

Four patients with posttraumatic long bone defects are reported hereinafter, all of whom are characterised by a complex course of therapy. After receiving detailed spoken and written information, all patients explicitly provided spoken and written informed consent to agree to the suggested treatment, including the implantation of mPCL-TCP scaffolds. Case characteristics and surgical treatment strategies applied to achieve bone healing are presented in Table 1. As part of the complex treatment course, the patients were treated with two-stage IMT and received mPCL-TCP scaffolds for an individual healing attempt during the second surgery of the IMT. The patient-specific scaffold prototypes for the four cases are displayed in Supplement 1. The pore size may vary depending on the exact geometry of the bone defect; however, 2 mm was respected as minimum. In all cases the scaffolds were used in combination with ABG. Therefore, the scaffolds designed with sufficiently large pores were carefully loaded manually with fresh bone graft. Particular care was taken to ensure that the pores were thoroughly and homogeneously loaded with bone graft, and in this regard the ease of access to the scaffolds from all sides proved beneficial. In the cases presented, satisfactory loading of the scaffolds with ABG was achieved in less than 5 min, and the properly sized pores combined with the suitable viscosity of the bone graft ensured its retention in the pore architecture, notably also during handling and implantation.

3.1. Case 1

A 23-year-old patient presented with a non-union of the distal left femur and a clinically relevant leg length discrepancy (LLD, ~4 cm) six months after sustaining an open (grade III) distal femur fracture. Initial injury treatment was ex domo using first an external fixator and then changing to a less invasive stabilization system (LISS, Synthes®) plate after successful treatment of a local infection. In our care, the initial
Table 1
Case characteristics and treatment strategies applied to achieve bone healing.

| Case number (patient age) | Anatomical site (index trauma)                                                                 | Bone defect morphology at the time of scaffold implantation (defect volume*) |
|---------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Case 1 (23 years)         | Distal femur metaphysis (grade III open fracture)                                                | Extensive non-union with bone shortening causing a leg length discrepancy of ~4 cm (73.67 cm³**). |
| 0 months after index trauma | External fixator and treatment of local infection                                              |                                                                               |
| 2 months after index trauma | Procedural change to less invasive stabilization system (LISS, Synthes®) plate                |                                                                               |
| 6 months after index trauma | Open biopsy and initiation of IMT                                                             |                                                                               |
| 7 months after index trauma | Replacement of the LISS plate by a longer Non-Contact Bridging (NCB, Zimmer®) plate along with insertion of a tubular mPCL-TCP scaffold loaded with Cerament G® (BONESUPPORT AB) and RIA ABG |                                                                               |
| 8 months after scaffold implantation | Unrestricted pain-free ability to walk without the support of assistive devices; advanced bony fusion on radiographic imaging |                                                                               |
| Case 2 (27 years)         | Tibia shaft (grade III open fracture)                                                         | Extra-large 10 cm-sized segmental defect (47.13 cm³)                          |
| 0 months after index trauma | External fixator and treatment of local infection                                              |                                                                               |
| 0–5 months after index trauma | Partial resection of the tibia during a complicated course of treatment                        |                                                                               |
| 6 months after index trauma | Implantation of an Orthofix® external fixator (TrueLok™ Ring Fixation System) and initiation of IMT |                                                                               |
| 7 months after index trauma | Replacement of PMMA spacer by a tubular scaffold loaded with RIA ABG and Cerament G® (BONESUPPORT AB) and supplemented with rhBMP-2 |                                                                               |
| 12 months after scaffold implantation | Replacement external fixator with medial angular stable plate                                |                                                                               |
| 19 months after scaffold implantation | Bony fusion on CT scan                                                                      |                                                                               |
| 23 months after scaffold implantation | Implant removal; pain-free full weight bearing within 2 weeks                                |                                                                               |
| Case 3 (42 years)         | Femur shaft (complex multi-fragmentary fracture)                                               | Complex malunion (165.72 cm³)                                                |
| 0–5 months after index trauma | Initial treatment with external fixator and large fragment plate                             |                                                                               |
| 6–7 months after index trauma | Removal of the atypically inserted plate, sequestrectomy, and exchange of the external fixator with a lateral femoral hybrid fixator (Orthofix®) as well as a Vacuum Assisted Closure (VAC) therapy including its regular exchanges |                                                                               |
| 19 months after index trauma | Implantation of modular (two parts) 3D-printed mPCL-TCP scaffolds loaded with ABG and combined with plate osteosynthesis |                                                                               |
| 6 months after scaffold implantation | Radiographically confirmed relevant aneurous consolidation; pain-free full weight bearing using forearm crutches |                                                                               |
| 9 months after scaffold implantation | Radiographically confirmed progressing bony fusion                                           |                                                                               |
| Case 4 (30 years)         | Distal tibia metaphysis (complex multi-fragmentary lower leg fracture)                         | Irregularly shaped large defect (29.89 cm³)                                  |
| 0–4 months after index trauma | External fixator (fibula) and small diameter intramedullary wire (fibula)                     |                                                                               |
| 5 months after index trauma | Open biopsy                                                                                    |                                                                               |
| 5 months after index trauma | Change external fixator to an Orthofix® ring fixator (TrueLok™ Ring Fixation System) and insertion of Cerament V® (BONESUPPORT AB) into the medullary cavity |                                                                               |
| 19 months after index trauma | Procedural change to intramedullary nail fixation                                             |                                                                               |
| 20 months after index trauma | Early nail removal due to recurrent osteomyelitis                                              |                                                                               |
| 21 months after index trauma | External fixator and initiation of IMT                                                        |                                                                               |

(continued on next page)
treatment included an open biopsy of the femoral defect area and initiation of IMT, including implantation of a PMMA spacer. No microbial colonisation was revealed in the open biopsy and the patient received a tubular mPCL-TCP scaffold loaded with ABG harvested from the contralateral femur using the Reamer-Irrigator-Aspirator (RIA, Synthes®) device mixed with Cerament G® (BONESUPPORT AB, Lund, Sweden). As the LLD was also corrected, the LISS (Synthes®) plate on the lateral site was removed and a longer NCB (Non-Contact Bridging, Zimmer®) plate was implanted. In the same operation, to achieve additional stability, a Locking Compression Plate (Large Fragment System, Synthes®) was implanted medially. Eight months after scaffold implantation, the patient showed an unrestricted pain-free ability to walk without the support of assistive devices. Furthermore, plain radiographic imaging showed advanced bony fusion (Fig. 3).

### 3.2. Case 2

A 27-year-old patient underwent partial resection of the right tibia during a complicated course of treatment, including recurrent osteomyelitis, after a III° open lower leg fracture. Six months after the initial trauma, the patient was transferred to our hospital for further therapy of a 10 cm-sized segmental defect. IMT was initiated after extensive debridement and lavage, and a modified external fixator from Orthofix® (TrueLok™ Ring Fixation System) was implanted, allowing immediate full weight bearing post-surgery. Supplement 2 details the surgical course before scaffold implantation. After antibiotic treatment, the second stage of the IMT technique was followed. The antibiotic-impregnated PMMA spacer was replaced by a tubular mPCL-TCP scaffold loaded with ABG harvested from the contralateral femur using the RIA system mixed with Cerament G® and supplemented with a bone morphogenetic protein-2 (12 mg)-impregnated collagen membrane (INFUSE® Bone Graft, Medtronic; Fig. 4). Two months after surgery, radiographic imaging showed minor dorsal scaffold dislocation, which was surgically addressed by fixation with an additional dorsal plate and by transplantation of additional ABG harvested from the iliac crest. Notably, during this revision surgery, there was no apparent evidence of

### Table 1 (continued)

| Case number (patient age) | Anatomical site (index trauma) | Bone defect morphology at the time of scaffold implantation (defect volume*) |
|---------------------------|-------------------------------|--------------------------------------------------------------------------|
| 22 months after index trauma | Placement of LCP 3.5 (Synthes®) and implantation of two-part mPCL-TCP scaffold loaded with iliac crest and RIA ABG as well as Cerament V® | Pain-free full weight bearing using forearm crutches for additional support |
| 7 months after scaffold implantation | Radiographically confirmed bone formation inside and outside the fully interconnected scaffold architecture | |

* Bone defect volume was calculated by segmenting the CT image data and performing Boolean subtraction from an idealised intact bone volume.
** The calculated defect volume is very likely an underestimate of the actual defect volume, as CT data was used for the calculation from a scan with the bone in impacted, shortened plate fixation.

![Implantation scaffold](image1.png) ![1 month after implantation](image2.png) ![8 months after implantation](image3.png)

Fig. 3. An mPCL-TCP scaffold loaded with ABG was used to treat femoral non-union and leg length discrepancy (-4 cm) in a 23-year-old patient. The implanted LISS plate (Synthes®, A) was removed, and the patient received re-osteosynthesis using an NCB plate (nine holes, Zimmer®) laterally and LCP (eight-hole large fragment system, Synthes®) medially (B). At the short-term follow-up, delicate but adequate bone formation with full scaffold integration (C).
inflammation in the area around the scaffold. Intraoperatively taken samples remained sterile. Eleven months after scaffold implantation, significant bone formation was observed, and the modified external fixator was replaced with an additional medial angular stable plate that was implanted in a minimally invasive way. Twenty-three months after scaffold implantation, a CT scan showed bony fusion and hence implant removal was indicated (Fig. 5). Following the implant removal, the patient had no pain and underwent full weight bearing within 2 weeks without any assistive devices.

3.3. Case 3

This patient (42 years old) sustained a multi-fragmentary shaft fracture of the right femur due to a complex blast injury and was admitted with an infected pseudarthrosis. First, a multi-fragmentary fracture zone measuring approximately 13 cm and infected with multiresistant Gram-negative bacteria (4 multidrug-resistant Gram-negative bacteria (MRGN)) was treated. A detailed treatment course before scaffold implantation can be found in Supplement 3. Briefly, a lateral femoral hybrid fixator (Orthofix®) was applied, and infection consolidation was performed by removing the periosteum and infected bone fragments. Conditioning of the soft tissues was achieved with Vacuum Assisted Closure (VAC) and antibiotic therapy. At a total of 19 months after index trauma, due to radiographically diagnosed significant bony consolidation, the patient was able to bear full weight with the aid of forearm crutches (Fig. 7).

3.4. Case 4

This patient (30 years old) was admitted five months after a polytrauma with multi-fragment distal lower leg fracture treated with an external fixator (tibia) and a small diameter intramedullary wire (fibula). The initial open biopsy revealed bacterial colonisation by a methicillin-resistant staphylococcus aureus (MRSA), and systematic antimicrobial treatment was initiated accordingly. A complex treatment course was followed with evidence of MRSA-induced osteomyelitis, and the external fixator was changed to an Orthofix® ring fixator (TrueLok™ Ring Fixation System) and Cerament V® (BONESUPPORT AB, Lund, Sweden) inserted into the medullary cavity. An attempt at intramedullary nail fixation 19 months after trauma resulted in early nail removal due to recurrent osteomyelitis (Fig. 8). One month after replacement with an external fixator and antibiotic-loaded Vancomycin-enriched PMMA spacer insertion to initialize an IMT, a distinct bone defect was revealed in the area of the distal dorso-medial tibia. Subsequently, after a persistent infection had been ruled out (open biopsy), a 3D-printed scaffold was used to augment the area of the former multi-fragmentary fracture zone in order to allow the patient to bear full weight in the further course of treatment. Reaming of the medullary canal and Pridié drilling at the defect sites were performed. Then, the two-part mPCL-TCP scaffold fitting into the irregularly shaped defect was loaded with iliac crest and RIA bone graft (harvested from the contralateral femur) and secured with a cerclage. An LCP Proximal Femoral Plate 4.5/5.0 (locking compression plate, Synthes®) was implanted to achieve additional biomechanical stability (Fig. 6). Primary wound healing was observed, and six months after implantation of the scaffold, due to radiographically diagnosed significant bony consolidation, the patient was able to bear full weight with the aid of forearm crutches (Fig. 7).
Fig. 5. Complete bone regeneration achieved in an extra-large tibial segmental (10 cm) defect after implantation of an mPCL-TCP scaffold loaded with ABG and supplemented with rhBMP-2 (INFUSE® Bone Graft, Medtronic). Scaffold integration at the proximal and distal defect ends after one year (A) was observed, and an external fixator was exchanged with plate fixation. At 19 months after scaffold implantation, x-ray (B) and 3D reconstruction of the CT scan (C) showed bony fusion. At 23 months after scaffold implantation, functional reconstruction of the extra-large segmental defect was achieved and the osteosynthesis implants were removed (D).

Fig. 6. Treatment of large bone defect with complex malunion of the right femoral shaft with modular (two parts) 3D-printed mPCL-TCP scaffolds. Following comprehensive treatment of a posttraumatic septic defect pseudarthrosis, including implantation of a hybrid fixator (Orthofix®) to support stability during infect consolidation (A), 3D reconstruction of CT imaging data showed two distinguished femoral bone defects located antero-lateral and antero-medial and also the preferred plate osteosynthesis was integrated at an early stage in the surgical planning (B). Two geometrically matched 3D-printed mPCL-TCP scaffolds loaded with ABG (C) were implanted and combined with plate osteosynthesis. Proper fit of the modular two-part scaffold of the bone defect as per the pre-operative planning (see inset in D), was confirmed intra-operatively (D).
inserted into the Masquelet-membrane. Furthermore, Cerament V® of the fully interconnected large pore architecture (A). Further, progressing TCP scaffolds secured with stainless steel cerclage wire. 3D reconstruction of the convergence of 3D-printed slow degrading scaffolds with ABG & rhBMPs shows the versatility of SGBR to treat large to extra-large bone volumes, as in cases 1 and 2, to highly complex, irregularly shaped large defects, as in cases 3 and 4.

Moreover, very good clinical results were achieved when applied in combination with RIA bone graft in a patient with an extra-large tibial defect (case 2). Enhanced neovascularization and shorter distances for diffusion of oxygen supply and nutrients facilitated by the >70% porous scaffold might account for the beneficial biological environment, which results in less bone graft resorption, essential for functional bone regeneration [52]. Nonetheless, a large distance of the autograft from the host bone and limited soft tissue envelope are characteristic of tibial (extra-large) segmental defects, which lead to impaired blood and nutrient supply to the defect area and are ultimately associated with increased autograft resorption eventually resulting in impaired bone regeneration [53]. Therefore, evidence of successful use in both pre-clinical and clinical studies in improving neovascularization and nutrient transport as well as metabolic waste removal [42,44,54,55] has prompted our interdisciplinary team to include additional biological stimulation with rhBMP-2 for the optimal early bone regeneration in case 2 which had a long defect trajectory and limited tibial soft tissue coverage capacity.
indicated (D).

...growth factor-beta 1 and the osteoinductive factor BMP-2 contains growth factors like vascular endothelial growth factor, trans-

...IMT [24,56]. In vivo studies have shown that the Masquelet-membrane materials inside the Masquelet-membrane during the second surgery of the

...implanting osteoinductive or osteoconductive graft ma-

...T2 tibia nail (C). During short-term follow-up, removal of the intramedullary nail and multiple debridement due to a recurrent MRSA infection were

...Of note, contradictory results have been published regarding the

...of implanting osteoinductive or osteoconductive graft ma-

...of nail stabilization [44]. Furthermore, irregularly shaped bone defects,

...of MRSA osteomyelitis, the procedure was changed 12 months after application of the ring fixator to a Stryker® T2 tibia nail (C). During short-term follow-up, removal of the intramedullary nail and multiple debridement due to a recurrent MRSA infection were indicated (D).

...of medical biodegradable scaffolds

...Bone healing involves a range of cells, including signalling molecules and signalling pathways that govern the healing process [63,64]. Therefore, the application of a composite biodegradable scaffold with cells seems logical; however, equipping scaffolds with stem cells is a high-demanding process with several challenges. For instance, harvesting and ex vivo cultivation of cells have been associated with reduced osteogenic capacity, as well as with affecting the phenotype and behaviour of these cells [65,66]. As the biodegradable material is directly coupled with a biologic, comprehensive FDA class 3 regulatory approval applies [50] and, therefore, is subject to strict regulatory control by the relevant authorities [67]. Furthermore, although progenitor cells benefit from the support of 3D-printed biodegradable scaffolds [68], their application without the support of an extracellular matrix (ECM) shows insufficient osteogenic capacity [41]. Therefore, to heal a large-sized defect, an osteoinductive and osteoconductive environment paired with biomechanical stability is required (diamond concept) [69]. In line with this, in a pre-clinical segmental defect study, mineralized cell sheets with delayed injection of allogenic stem cells providing a suitable ECM showed improved bone regeneration [39]. In particular, the ECM of ABG contains a reservoir of complete and specific structural and signalling proteins at a physiological dose and in a “non-recombinant” state [70]. Therefore, with intraoperative packing of biodegradable scaffolds with bone grafts, a highly osteogenic environment is achieved with an unquestionable capacity to regenerate large bone defects [43,44].

...delayed injection of allogenic stem cells providing a suitable ECM showed improved bone regeneration [39]. In particular, the ECM of ABG contains a reservoir of complete and specific structural and signalling proteins at a physiological dose and in a “non-recombinant” state [70]. Therefore, with intraoperative packing of biodegradable scaffolds with bone grafts, a highly osteogenic environment is achieved with an unquestionable capacity to regenerate large bone defects [43,44].

Fig. 8. Complex course of treatment after polytrauma with distal lower leg fracture and recurrent MRSA-induced osteomyelitis. Initial treatment included open biopsy (test result: MRSA), removal of the implants (A), and implantation of an Orthoﬁx® ring fixator (TrueLok™ Ring Fixation System) along with Cerament® insertion in the medullary cavity of the right tibia (B). After treatment of the MRSA osteomyelitis, the procedure was changed 12 months after application of the ring fixator to a Stryker® T2 tibia nail (C). During short-term follow-up, removal of the intramedullary nail and multiple debridement due to a recurrent MRSA infection were indicated (D).
these cases, plate osteosynthesis especially was successfully integrated into the treatment concept (Figs. 6 and 9). It is important to note that especially in cases with bone defects and concomitant malunion, it is crucial to exclude bony misalignment in preoperative planning or to address its treatment in the scaffold design process, choice of internal and/or external fixation device and overall surgical planning.

To the best of our knowledge, we present the first case series of patients with posttraumatic long bone defects receiving individually tailored SGBR strategies. We reviewed the patient cases according to the proposed clinical reporting methods for medical devices for reconstruction of long bone defects [72] and observed radiographically and non-invasively appropriate limb alignment, stability and bone healing during follow-up. Moreover, full weight bearing, functional limb recovery and high patient satisfaction were achieved in all cases. However, firstly, several tightly regulated remodelling cycles involving a balance between resorption and formation are required before complete bone regeneration is achieved [73], and secondly, full resorption of mPCL-TCP scaffolds takes up to 48–60 months [74]. Therefore, in the presented patient cases, ongoing clinical follow-up is required before ultimately complete bone remodelling and thus successful completion of treatment can be confirmed. Long-term follow-up of several years with frequent check-ups is a major challenge for clinical studies in the field of these highly complex large long bone defects. Therefore, based on the promising short-to-medium-term results presented in the four cases, the planning of multi-centre long-term clinical trials has been initiated.

5. Conclusion

This case study indicates that patient-specific SGBR represents a transformative treatment concept for large bone defects, including complex and irregularly shaped malunions. In SGBR, the scaffold design objective is not to replicate/copy the physical structure of the organ bone, but rather to guide tissue development throughout the entire regeneration process in order to facilitate physiological bone remodelling. We demonstrate that a scaffold morphology design rooted in these principles allows both the ABG and the host tissue to promote new tissue formation by providing both a surface and void space, which promotes the attachment, migration, proliferation and desired differentiation of connective tissue progenitors throughout the region where new tissue is needed.

Authorship statement

Conception and design of study: ML, DWH, FH; acquisition of data: ML, HD, HA; analysis and/or interpretation of data: SS, BH, M-LW; drafting the manuscript: ML, DWH, HD, FH; revising the manuscript critically for important intellectual content: M-LW, HA, SS, BH; approval of the version of the manuscript to be published: ML, SS, BH, M-LW, HD, HA, DWH, FH.

Ethical approval statement

As described in the results section the patients received mPCL-TCP scaffolds for an individual healing attempt. Since individual healing attempts are not considered human experimentation under current German law, no application to the Ethics Committee is required. However, as described in the manuscript, after receiving detailed spoken and written information, all patients explicitly provided spoken and written informed consent to agree to the suggested treatment, including the implantation of mPCL-TCP scaffolds.
Declaration of competing interest

DWH is a co-founder and shareholder of Osteopore International Pty Ltd., a company specialized in 3D-printed bioresorbable implants to assist with bone healing. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors gratefully acknowledge the support of the Alexander von Humboldt Foundation and the Queensland University of Technology, jointly funding a Feodor Lynen Research Fellowship of the Alexander von Humboldt Foundation awarded to Markus Laubach. Furthermore, financial support for this project was provided by the Australian Research Council via the ARC Training Centre for Multiscale 3D Imaging, Modelling and Manufacturing (M3D Innovation, project IC 180100008). We thank Osteopore International Pty Ltd. for their valuable cooperation and for providing the scaffold prototype images of cases 3 and 4 (Supplement 1).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jot.2022.04.004.

References

[1] Hadjidakis DJ, Androulakis IL. Bone remodeling. Ann N Y Acad Sci 2006;1092:985–96 [eng].
[2] Hak DJ, Fitzpatrick D, Bishop JA, Marsh JL, Tilp S, Schnettler R, et al. Delayed salvage of failed oncologic long bone reconstruction and pathologic fractures. Rev Chir Orthop 2012;98(1):79–84 [eng].
[3] Berner A, Henkel J, Woodruff MA, Saifzadeh S, Kirby G, Schuetz MA, et al. Minimal invasive inflammatory injection of algogenic bone marrow stromal cells regenerates large bone defects in an ovine preclinical animal model. Stem Cells Transl Med 2015;4(9):604–13 [eng].
[4] Henkel J, Reichter JC, Epari DR, Saizadeh S, Berner A, Schell H, et al. Polycaprolactone scaffold and reduced rhBMP-7 dose for the regeneration of critical-sized defects in sheep tibiae. Biomaterials 2017;34(38):9960–8.
[5] Durand M. Masquelet induced membrane technique for the surgical treatment of large bone defects: the reasons for successes and failures. Am J Biomed Sci Res 2011;5:1–21 [eng].
[6] Henkel J, Reichter JC, Epari DR, Saizadeh S, Berner A, Schell H, et al. Polycaprolactone scaffold and reduced rhBMP-7 dose for the regeneration of critical-sized defects in sheep tibiae. Biomaterials 2017;34(38):9960–8.
[7] Durand M. Masquelet induced membrane technique for the surgical treatment of large bone defects: the reasons for successes and failures. Am J Biomed Sci Res 2011;5:1–21 [eng].
[8] Berner A, Henkel J, Woodruff MA, Saizadeh S, Kirby G, Schuetz MA, et al. Delayed minimally invasive inflammatory injection of algogenic bone marrow stromal cells regenerates large bone defects in an ovine preclinical animal model. Stem Cells Transl Med 2015;4(9):604–13 [eng].
[9] Henkel J, Reichter JC, Epari DR, Saizadeh S, Berner A, Schell H, et al. Polycaprolactone scaffold and reduced rhBMP-7 dose for the regeneration of critical-sized defects in sheep tibiae. Biomaterials 2017;34(38):9960–8.
[10] Durand M. Masquelet induced membrane technique for the surgical treatment of large bone defects: the reasons for successes and failures. Am J Biomed Sci Res 2011;5:1–21 [eng].

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jot.2022.04.004.

References

[1] Hadjidakis DJ, Androulakis IL. Bone remodeling. Ann N Y Acad Sci 2006;1092:985–96 [eng].
[2] Hak DJ, Fitzpatrick D, Bishop JA, Marsh JL, Tilp S, Schnettler R, et al. Delayed salvage of failed oncologic long bone reconstruction and pathologic fractures. Rev Chir Orthop 2012;98(1):79–84 [eng].
[3] Berner A, Henkel J, Woodruff MA, Saifzadeh S, Kirby G, Schuetz MA, et al. Minimal invasive inflammatory injection of algogenic bone marrow stromal cells regenerates large bone defects in an ovine preclinical animal model. Stem Cells Transl Med 2015;4(9):604–13 [eng].
[4] Henkel J, Reichter JC, Epari DR, Saizadeh S, Berner A, Schell H, et al. Polycaprolactone scaffold and reduced rhBMP-7 dose for the regeneration of critical-sized defects in sheep tibiae. Biomaterials 2017;34(38):9960–8.
[5] Durand M. Masquelet induced membrane technique for the surgical treatment of large bone defects: the reasons for successes and failures. Am J Biomed Sci Res 2011;5:1–21 [eng].
[6] Berner A, Henkel J, Woodruff MA, Saizadeh S, Kirby G, Schuetz MA, et al. Delayed minimally invasive inflammatory injection of algogenic bone marrow stromal cells regenerates large bone defects in an ovine preclinical animal model. Stem Cells Transl Med 2015;4(9):604–13 [eng].
[7] Durand M. Masquelet induced membrane technique for the surgical treatment of large bone defects: the reasons for successes and failures. Am J Biomed Sci Res 2011;5:1–21 [eng].

[49] Williams DF. The biomaterials conundrum in tissue engineering. Tissue Eng 2014; 20(7-8):1129–31 [English].

[50] Hollister SJ, Murphy WL. Scaffold translation: barriers between concept and clinic. Tissue Eng B Rev 2011;17(6):459–74 [eng].

[51] O’Keefe RJ, Mao J. Bone tissue engineering and regeneration: from discovery to the clinic—an overview. Tissue Eng B Rev 2011;17(6):389–92 [English].

[52] Dirmagl U, Duda GN, Grainger DW, Reinske P, Koenen R. Reproducibility, relevance and reliability as barriers to efficient and credible biomedical technology translation. Adv Drug Deliv Rev 2022;114118.

[53] Phieffer LS, Goulet JA. Delayed unions of the tibia. J Bone Joint Surg Am 2006; 88(1):206–16 [eng].

[54] Pearson HB, Mason DE, Kegelman CD, Zhao L, Dawahare JH, Kacena MA, et al. Effects of bone morphogenetic protein-2 on neovascularization during large bone defect regeneration. Tissue Eng Part A 2019;25(23-24):1623–34 [eng].

[55] Haukbruck P, Tanner MC, Vlachopoulos W, Hagelskamp S, Miksa M, Öber J, et al. Comparison of the clinical effectiveness of Bone Morphogenic Protein (BMP) -2 and -7 in the adjunct treatment of lower limb nonunions. J Orthop Traumatol: Surgery & Research 2018;10(4):1241–8.

[56] Christou C, Oliver RA, Yu Y, Walsh WR. The Masquelet technique for membrane induction and the healing of ovine critical sized defects. PLoS One 2014; 9(12):e114122 [English].

[57] Gruber HE, Getrys FK, Montijo HE, Starman JS, Bayoumi E, Nelson KJ, et al. Genomewide molecular and biologic characterization of biomembrane formation adjacent to a methacrylate spacer in the rat femoral segmental defect model. J Orthop Trauma 2013;27(5):290–7 [eng].

[58] Pelissier P, Masquelet AC, Bareille R, Pelissier SM, Amedee J. Induced membranes to facilitate reconstruction of massive segmental diaphyseal bone defects: an ovine model. Vet Surg 2006;35(5):445–52 [Eng].

[59] Viateau V, Guillemin G, Logeart D, Oudina K, Sedel L, et al. Induction of bone formation: the translation enigma. Front Bioeng Biotechnol 2018;6. 74-74. [eng].

[60] Zhang W, Zhu C, Wu Y, Ye D, Wang S, Dou D, et al. VEGF and BMP-2 promote bone regeneration by facilitating bone marrow stem cell homing and differentiation. Eur Cell Mater 2014;27(12):1.

[61] Viateau V, Guillemin G, Bousson V, Oudina K, Hannouche D, Sedel L, et al. Long-bone critical-size defects treated with tissue-engineered grafts: a study on sheep. J Orthop Res 2007;25(6):741–9 [eng].

[62] Metsmakers WJ, Claes G, Terryn PJ, Belmans A, Hockstra H, Nijs S. Reamer-Irrigator-Aspirator bone graft harvesting for treatment of segmental bone loss: analysis of defect volume as independent risk factor for failure. Eur J Trauma Emerg Surg 2019;45(1):21–9 [eng].

[63] Winkler T, Sans FA, Duda GN, Schmidt-Bleek K. A review of biomaterials in bone defect healing, remaining shortcomings and future opportunities for bone tissue engineering. Bone & Joint Research 2018;7(3):232–43.

[64] Schlickewei CW, Kleinerz H, Thiesen DM, Mader K, Priemel M, Frosch KH, et al. Current and future concepts for the treatment of impaired fracture healing. Int J Mol Sci 2019;20(22) [Eng].

[65] Adamzyk C, Emond T, Falkenstein J, Tolba R, Jahnken-Dechent W, Lethaus B, et al. Different culture media affect proliferation, surface epitope expression, and differentiation of ovine MSC. 2013 Stem Cell Int 2013:387324. 24. [eng].

[66] Coelho MJ, Cabral AT, Fernande MH. Human bone cell cultures in biocompatibility testing. Part I: osteoblastic differentiation of serially passaged human bone marrow cells cultured in alpha-MEM and in DMEM. Biomaterials 2000;21(11):1087–94 [Eng].

[67] Sakai D, Shol J, Foldager CB, Sato M, Watanabe M. Regenerative technologies to bed side: evolving the regulatory framework. J Orthop Translat 2017;9:1–7 [Eng].

[68] Henkel J, Woodruff MA, Epari DR, Steck R, Glatt V, Dickinson IC, et al. Bone regeneration based on tissue engineering conceptions — a 21st century perspective. Bone Res 2015;1(1):216–48.

[69] Giannoudis PV, Einhorn TA, Marsh D. Fracture healing: the diamond concept. Injury 2007;38(Suppl 4):S3–6 [Eng].

[70] Klar KM. The induction of bone formation: the translation enigma. Front Bioeng Biotechnol 2018;6. 74-74. [Eng].

[71] Buijze GA, Richardson S, Jupiter JB. Successful reconstruction for complex malunions and nonunions of the tibia and femur. JBJS 2011;93(5):485–92.

[72] Zhang M, Matrinilma JP, Tsoi JKH, Liu W, Cui X, Lu WW, et al. Recent developments in biomaterials for long-bone segmental defect reconstruction: a narrative overview. J Orthopaedic Traumatol 2019;22:26–33 [eng].

[73] Kenkre J, Bassett J. The bone remodelling cycle. Ann Clin Biochem 2018;55(3): 308–27.

[74] Woodruff MA, Lange C, Reichert J, Berner A, Chen F, Fratzl P, et al. Bone tissue engineering: from bench to bedside. Mater Today 2012;15(10):430–5.